drugset / Trial / NCT05320120

Investigation of Intranasal Ketamine Related Changes in Attentional Brain Networks With Functional and Structural MRI

NCT05320120

Phase 1 Completed 33 enrolled Rupert Lanzenberger
RandomizedCrossoverDouble-blindBasic science

Summary

Subanesthetic ketamine is currently used as a rapid-acting antidepressant. It is an antagonist of the N-methyl-d-aspartate (NMDA) receptor, but former results indicate that its action also depends on the noradrenaline system and the locus coeruleus (LC). Based on this known impact of ketamine on the sympathetic nervous system the aim of this study is to investigate the effects of intranasal esketamine on LC related attentional brain networks in task based functional MRI, to relate those attention network changes to behavioural measures and to predict ketamine related attention network changes by brain structure.

Timeline

Start
2022-06-01
Primary completion
2023-06-21
Completion
2023-06-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Esketamine Other / unclassified 56 mg Intranasal

Indications

No indication recorded.